本帖最后由 老马 于 2013-3-13 13:43 编辑
2 g. i- u/ Y) j5 R
! {, j3 E- V' A! Y; B: S健择（吉西他滨）+顺铂+阿瓦斯汀
5 ^7 D' z- \8 `1 A Gemzar +Cisplatin + Avastin' I& N% w: \9 W# t8 n- D! D
http://annonc.oxfordjournals.org/content/21/9/1804.full9 h9 w, j9 C/ E9 Q2 c# Y: ?1 m) G
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
$ b- Q/ V' ^" C' U- QPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
0 G: @0 I) j7 `( }* _- WResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
7 @7 q* R, W( l) B; }1 B
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1140)
) T9 r* w: w0 {( z( u1 i8 t1 d$ X
华为网盘附件：
- C! _% u) n/ q【华为网盘】ava.JPG
' W" H2 F! o9 n |
11011102001537 )
显身卡
